Macular diseases are becoming more prevalent among the elderly population, with several equally effective treatment options available, including biosimilar drugs which could offer significant cost savings.

This study aimed to highlight the rising expenses associated with purchasing anti-VEGF drugs due to an increasing number of patients and the introduction of new medications. Additionally, it seeks to encourage healthcare professionals to consider using biosimilar drugs more frequently.

Data on patient numbers categorized by gender, the quantity of drug vials used and the corresponding expenditure on anti-VEGF medications for treating macular diseases have been collected and compared for the second half of 2022 and 2023 in an Italian healthcare institution.

The study revealed a noticeable uptick in treatments and healthcare costs, with 767 patients treated and a total expenditure of €715,630.22 during the analyzed periods. This represented an increase of 99 patients, 185 injections, and €134,465.74 compared to the preceding period.

Given the escalating expenses associated with macular disease therapy, it is imperative for central governments and regulatory administrations to intensify efforts to monitor pharmaceutical spending and establish guidelines promoting the adoption of biosimilar drugs. These alternatives offer comparable clinical efficacy while yielding substantial healthcare cost savings.